Cargando…

mEH Tyr113His polymorphism and the risk of ovarian cancer development

BACKGROUND: The causes of ovarian cancer are complex and may be influenced by many factors, including polymorphism in the microsomal epoxide hydrolase (mEH) gene. Previous work suggests an association between the Tyr113His mEH polymorphism rs1051740 and susceptibility to ovarian cancer, but the resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jian-Hong, Zhang, Zhi-Ming, Li, Le-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681615/
https://www.ncbi.nlm.nih.gov/pubmed/23742121
http://dx.doi.org/10.1186/1757-2215-6-40
_version_ 1782273283412983808
author Zhong, Jian-Hong
Zhang, Zhi-Ming
Li, Le-Qun
author_facet Zhong, Jian-Hong
Zhang, Zhi-Ming
Li, Le-Qun
author_sort Zhong, Jian-Hong
collection PubMed
description BACKGROUND: The causes of ovarian cancer are complex and may be influenced by many factors, including polymorphism in the microsomal epoxide hydrolase (mEH) gene. Previous work suggests an association between the Tyr113His mEH polymorphism rs1051740 and susceptibility to ovarian cancer, but the results have been inconsistent. METHODS: PubMed, EMBASE, Google Scholar, and Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association between Tyr113His mEH polymorphism and susceptibility to ovarian cancer. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. RESULTS: Five studies involving 2,566 cases and 2,839 controls were included. Although the polymorphism did not affect ovarian cancer risk in the allelic contrast model (OR = 0.99, 95% CI = 0.83-1.17, P = 0.86), the mutant CC genotype was significantly associated with increased risk in the homozygote comparison (OR = 1.20, 95% CI = 1.01-1.43, P = 0.04) and recessive genetic models (OR = 1.20, 95% CI = 1.01-1.41, P = 0.03). The wild-type TT genotype was not associated with higher or lower ovarian cancer risk in the dominant genetic model (OR = 1.04, 95% CI = 0.83-1.29, P = 0.74). These results were robust to sensitivity analysis. CONCLUSIONS: The CC genotype of Tyr113His mEH may confer increased risk of ovarian cancer. These conclusions should be verified in large and well-designed studies.
format Online
Article
Text
id pubmed-3681615
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36816152013-06-14 mEH Tyr113His polymorphism and the risk of ovarian cancer development Zhong, Jian-Hong Zhang, Zhi-Ming Li, Le-Qun J Ovarian Res Research BACKGROUND: The causes of ovarian cancer are complex and may be influenced by many factors, including polymorphism in the microsomal epoxide hydrolase (mEH) gene. Previous work suggests an association between the Tyr113His mEH polymorphism rs1051740 and susceptibility to ovarian cancer, but the results have been inconsistent. METHODS: PubMed, EMBASE, Google Scholar, and Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association between Tyr113His mEH polymorphism and susceptibility to ovarian cancer. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. RESULTS: Five studies involving 2,566 cases and 2,839 controls were included. Although the polymorphism did not affect ovarian cancer risk in the allelic contrast model (OR = 0.99, 95% CI = 0.83-1.17, P = 0.86), the mutant CC genotype was significantly associated with increased risk in the homozygote comparison (OR = 1.20, 95% CI = 1.01-1.43, P = 0.04) and recessive genetic models (OR = 1.20, 95% CI = 1.01-1.41, P = 0.03). The wild-type TT genotype was not associated with higher or lower ovarian cancer risk in the dominant genetic model (OR = 1.04, 95% CI = 0.83-1.29, P = 0.74). These results were robust to sensitivity analysis. CONCLUSIONS: The CC genotype of Tyr113His mEH may confer increased risk of ovarian cancer. These conclusions should be verified in large and well-designed studies. BioMed Central 2013-06-06 /pmc/articles/PMC3681615/ /pubmed/23742121 http://dx.doi.org/10.1186/1757-2215-6-40 Text en Copyright © 2013 Zhong et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhong, Jian-Hong
Zhang, Zhi-Ming
Li, Le-Qun
mEH Tyr113His polymorphism and the risk of ovarian cancer development
title mEH Tyr113His polymorphism and the risk of ovarian cancer development
title_full mEH Tyr113His polymorphism and the risk of ovarian cancer development
title_fullStr mEH Tyr113His polymorphism and the risk of ovarian cancer development
title_full_unstemmed mEH Tyr113His polymorphism and the risk of ovarian cancer development
title_short mEH Tyr113His polymorphism and the risk of ovarian cancer development
title_sort meh tyr113his polymorphism and the risk of ovarian cancer development
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681615/
https://www.ncbi.nlm.nih.gov/pubmed/23742121
http://dx.doi.org/10.1186/1757-2215-6-40
work_keys_str_mv AT zhongjianhong mehtyr113hispolymorphismandtheriskofovariancancerdevelopment
AT zhangzhiming mehtyr113hispolymorphismandtheriskofovariancancerdevelopment
AT lilequn mehtyr113hispolymorphismandtheriskofovariancancerdevelopment